Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Immutep: LAG-3 Progress In-House And Via Partners

Published 08/30/2018, 08:56 AM
Updated 07/09/2023, 06:31 AM

Immutep Ltd (AX:IMM) has reported encouraging progress from its in-house and partnered programmes over the past few months. Interim data from the TACTI-mel combo study included a 61% response rate from the start of the Keytruda monotherapy screening period among subjects who went on to receive eftilagimod alpha (efti or IMP321) combo therapy. Partners GSK and Novartis are progressing their in-licensed LAG-3 programmes into Phase II or proof of concept studies, which increases the likelihood that these programmes will return significant value to Immutep. Our valuation has increased to A$510m or A$0.17/share (from A$439m or A$0.14/share).

Immutep

Encouraging TACTI-mel data – update due November

Patients in the first three TACTI-mel cohorts showed a 33% response rate from the start of efti/Keytruda combo therapy and 61% from the start of the Keytruda monotherapy screening period. The six-patient additional cohort is fully recruited; treatment with efti started at the same time as Keytruda (vs 12 weeks after the start of Keytruda therapy in the first three cohorts). A data update is due in November.

To read the entire report Please click on the pdf File Below:


Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.